Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 8, 2016-09 ,pp. : 945-955

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 117-120

Bentham Science Publishers

Access to resources Recommend Favorite

Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer

By  

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 252-266

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 188-204

Bentham Science Publishers

Access to resources Recommend Favorite